SCHEMBL24254516

SCHEMBL24254516

CC(=O)Nc1cc(S(=O)(=O)Cl)ccc1OC(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 3/20 0.50
RECQL P46063 1/20 0.47
CNR2 P34972 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
TNNI3K Q59H18 2/20 0.41
GSTO1 P78417 1/20 0.40
S100A9 P06702 1/20 0.40
LMNA P02545 1/20 0.40
IDH2 P48735 1/20 0.40
EPHX2 P34913 1/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254517 0.84 GSTO1 (0.49) KMT2AMEN1ALDH1A1RECQLGSTO1
SCHEMBL1553581 0.83 KMT2A (0.63) KMT2AMEN1ALDH1A1LMNAMAPK1
SCHEMBL9953365 0.80 CYP1A2 (0.58) KMT2AMEN1ALDH1A1CYP1A2CYP2C9
SCHEMBL17681593 0.79 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1RECQLCYP1A2
SCHEMBL9973781 0.79 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1RECQLCYP1A2
SCHEMBL9973787 0.77 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1RECQLCYP1A2
SCHEMBL17681780 0.77 CYP1A2 (0.70) KMT2AMEN1ALDH1A1RECQLCYP1A2
SCHEMBL1527189 0.77 ALDH1A1 (0.55) ALDH1A1RECQLCYP1A2CYP2C9CYP2C19
SCHEMBL1602690 0.77 CA1 (0.55) KMT2AMEN1ALDH1A1CA1CA2
SCHEMBL24254558 0.77 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1RECQLCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 KMT2A 326/4885MEN1 3058/4885ALDH1A1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.